Biogen Inc

Biogen Inc


Market Cap$32.8B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Biogen IncBiogen Inc28.10%-3.4-

Target Price by Analysts

26% upsideBiogen Target Price DetailsTarget Price

Current Fair Value

41.7% upside

Undervalued by 41.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$32.80 Billion
Enterprise Value-
Dividend Yield$0.0 (0.0%)
Earnings per Share$8.0
Outstanding Shares145,596,895
Avg 30 Day Volume1,014,263


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio28.11
Price to Sales3.42
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Biogen Inc

7,300 employees
CEO: Josephine Price

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...